Answers are grounded in this paper and cite their sources.
After implantation, the maternal immune system must tolerate the semi-allogeneic embryo for approximately 280 days of human pregnancy.Regulation and adaptation of the immune system is critical during this period, and any disorder in the balance of the immune system leads to reproductive disorders such as recurrent pregnancy loss.Studies show that immunotherapy plays an important role in improving complications caused by the immune system, including recurrent pregnancy loss, and is used as a critical treatment factor of recurrent miscarriage.Various immunomodulatory agents, namely, corticosteroids, tacrolimus, aspirin and heparin and cyclosporins, intravenous immunoglobulins, intralipids, etc., prevent maternal immune system attack to the semiallogeneic fetus and production and proliferation of cytokines And harmful cells for pregnancy by exerting anti-inflammatory and immunomodulatory effects with different mechanisms.Also, factors such as G-CSF and GM-CSF have a positive effect on the pregnancy process by recruitment and differentiated leukocytes in the placenta tissue and also helping the placenta grow better.This review examines the types of immunotherapies commonly used in the treatment of recurrent miscarriage and future treatments being developed.
No takes yet. Share an insight, caveat, or question.
Panah et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: